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Alzheimer's disease (AD) is a gradually debilitating disease that leads to dementia. The molecular me-
chanisms underlying AD are still not clear, and at present no reliable biomarkers are available for the
early diagnosis. In the last several years, together with oxidative stress and neuroinﬂammation, altered
cholesterol metabolism in the brain has become increasingly implicated in AD progression. A signiﬁcant
body of evidence indicates that oxidized cholesterol, in the form of oxysterols, is one of the main triggers
of AD. The oxysterols potentially most closely involved in the pathogenesis of AD are 24-hydro-
xycholesterol and 27-hydroxycholesterol, respectively deriving from cholesterol oxidation by the en-
zymes CYP46A1 and CYP27A1. However, the possible involvement of oxysterols resulting from choles-
terol autooxidation, including 7-ketocholesterol and 7β-hydroxycholesterol, is now emerging. In a sys-
tematic analysis of oxysterols in post-mortem human AD brains, classiﬁed by the Braak staging system of
neuroﬁbrillary pathology, alongside the two oxysterols of enzymatic origin, a variety of oxysterols de-
riving from cholesterol autoxidation were identiﬁed; these included 7-ketocholesterol, 7α-hydro-
xycholesterol, 4β-hydroxycholesterol, 5α,6α-epoxycholesterol, and 5β,6β-epoxycholesterol. Their levels
were quantiﬁed and compared across the disease stages. Some inﬂammatory mediators, and the pro-
teolytic enzyme matrix metalloprotease-9, were also found to be enhanced in the brains, depending on
disease progression. This highlights the pathogenic association between the trends of inﬂammatory
molecules and oxysterol levels during the evolution of AD. Conversely, sirtuin 1, an enzyme that regulates
several pathways involved in the anti-inﬂammatory response, was reduced markedly with the pro-
gression of AD, supporting the hypothesis that the loss of sirtuin 1 might play a key role in AD. Taken
together, these results strongly support the association between changes in oxysterol levels and AD
progression.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B.V. This is an open access article u
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Leonarduzzi).1. Introduction
Alzheimer's disease (AD) is a slowly progressive neurodegen-
erative disorder that leads to dementia. It is characterized by in-
tracellular neuroﬁbrillary tangles (NFT) made of hyperpho-
sphorylated tau (p-tau) protein and extracellular amyloid beta
(Aβ) plaques [1]. Although experimental evidence conﬁrms that
Aβ accumulation precedes and drives NFT formation, thereby fa-
cilitating the development of tau pathology [2,3], intraneuronal
lesions consisting of abnormal tau protein are seen to develop
from the onset of AD until the end-phase of the underlying pa-
thological process [4]. Recent evidence indicates that the AD
process begins in nuclei of the lower brainstem, which send dif-
fuse projections to a variety of vulnerable brain sites and, innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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At present, no reliable biomarkers for early diagnosis of AD are
available; only a provisional diagnosis can be made, and that
generally not until the ﬁnal phase of the disease. Deﬁnitive diag-
nosis requires post-mortem evaluation of NFT and senile plaques in
the brain [9,10]. Thanks to the development of sensitive im-
munocytochemical methods, it is now possible to reliably detect
intraneuronal neuroﬁbrillary location and the severity of changes
with disease progression. The Braak staging system for in-
traneuronal lesions differentiates among initial, intermediate, and
late phases of the disease process, in both non-symptomatic and
symptomatic AD patients; six AD stages (I–VI) have been identiﬁed
(transentorhinal stages I–II: clinically silent cases; limbic stages Ill–
IV: incipient AD; neocortical stages V-VI: fully developed AD) [11].
The molecular mechanisms underlying the disease are still not
clear, and remain controversial. However, in recent years, it has
become increasingly clear that altered cholesterol metabolism in
the brain is involved in AD development, and hypercholester-
olemia is considered a potential risk factor [12–15]. Thanks to
consistent research evidence, it is now believed that cholesterol
oxidized products, known as oxysterols, are the link connecting
altered cholesterol metabolism and hypercholesterolemia to this
neurodegenerative disease [14].
Cholesterol is produced in situ in the brain, where its content
exceeds that of any other organ. In order to prevent cholesterol
accumulation in the brain, it can be oxidized by enzymes of the
cytochrome p450 family, forming oxysterols. In particular, cho-
lesterol is primarily converted by CYP46A1 into 24-hydro-
xycholesterol (24-OH), also called cerebrosterol, which, unlike its
parent compound, is able to cross the blood brain barrier (BBB)
and reaches the peripheral circulation. Another oxysterol present
in the brain is 27-hydroxycholesterol (27-OH), produced by
CYP27A1 and then transformed into 7α-hydroxy-3-oxo-4-choles-
tenoic acid (7-OH-4-C) by the enzyme CYP7B; 7-OH-4-C crosses
the BBB, and reaches the liver where it is eliminated [16]. How-
ever, most 27-OH ﬂows in the opposite direction, from the circu-
lation into the brain. In addition to those oxysterols, others de-
riving from cholesterol autoxidation have been identiﬁed post-
mortem in human AD brains, including 7-ketocholesterol (7-K),
7α-hydroxycholesterol (7α-OH), 4β-hydroxycholesterol (4β-OH),
5α,6α-epoxycholesterol (α-epoxy), and 5β,6β-epoxycholesterol
(β-epoxy); the trend of their concentrations during disease stages
has been examined [17].
In the normal aging brain, oxysterol homeostasis is closely
controlled by pathways regulating both cholesterol biosynthesis
and efﬂux, and oxysterol enzymatic formation. Moreover, several
routes by which cholesterol metabolites may be exported from the
brain or imported into it have been demonstrated [18,19]. How-
ever, toxic amounts of oxysterols can accumulate in the brain, in
particular due to the increased ﬂux of these sterol molecules from
the peripheral circulation into the brain; this is caused by in-
creased permeability of the BBB, owing to its impairment [20].
Aging may lead to partial disruption of BBB integrity, but the
barrier's function can also be signiﬁcantly affected in neurode-
generative diseases, including AD. Among the causes of this im-
pairment, hypercholesterolemia associated to oxidative stress can
damage the BBB [21]; furthermore, BBB integrity and function can
be partially damaged by oxysterols themselves [22]. Oxysterols
that accumulate in the brain certainly play a fundamental role in
AD development, by enhancing oxidative stress and inﬂammation,
as well as Aβ formation and accumulation, with subsequent neu-
ron death [14].
It has been widely reported that increased oxidative stress in
the brain during AD intensiﬁes neurodegeneration, by favoring
generation of reactive oxygen species (ROS), lipid peroxidation,
and oxysterol formation [23,24]. Apart from oxidative stress, ADpathology is also associated with neuroinﬂammation [14,25,26].
AD development is characterized by the enhancement of many
inﬂammatory mediators in the brain, including several cytokines
and proteolytic enzymes, such as matrix metalloprotease 9 (MMP-
9), produced by microglia, by astrocytes, and even by neurons
[25,26]. Up-regulation of the enzyme cyclooxigenase 2 (COX-2) has
also been observed during inﬂammation, mainly in neurons but
also in reactive microglia [27,28]. Moreover, during AD progres-
sion, a marked reduction of sirtuin-1 (SIRT-1) has been demon-
strated. SIRT-1 is a deacetylase that regulates several cellular
pathways, involved not only in the anti-inﬂammatory response
but also in other neuroprotective mechanisms through which it
promotes neuron survival, by deacetylating a broad spectrum of
molecules [29]. In this connection, it has been hypothesized that
the loss of SIRT-1 protein in the brain contributes to the patho-
genesis of AD [30].
The study elucidates the pathogenic association between
changes in the concentration of several oxysterols present in AD
brains and the progression of the disease, as well as the associa-
tion between oxysterol levels and neuroinﬂammation. In this
connection, a systematic analysis of oxysterols at different Braak
stages of the AD brain was carried out. Several oxysterols of both
enzymatic and non-enzymatic origin, some never previously
identiﬁed in the brain, were found and quantiﬁed, and the proﬁle
of their amounts was found to clearly differ depending on the
severity of the disease. Moreover, taking into account the different
Braak stages, a new possible association between inﬂammatory
molecules and oxysterol levels trend throughout the evolution of
this disease emerges. Lastly, the results support the hypothesis
that the loss of SIRT-1 might play a key role in AD progression.2. Materials and methods
2.1. Histological and immunohistochemical analysis
In the brains included in the present study, routine neuro-
pathological examination excluded relevant lesions such as tu-
mors, signiﬁcant vascular disease/stroke, or inﬂammation. Tissue
from the frontal and occipital cortex of thirteen AD patients and
four control subjects were obtained from the Carlo Besta Institute
of Neurology (Milan, Italy).
Specimens were assessed histologically by hematoxylin and
eosin, cresyl violet for Nissl substance, Heidenhein-Woelcke for
myelin and thioﬂavine S for amyloid as well as by im-
munohistochemistry using antibodies against Aβ (4G8 1:4000,
Signet Laboratories, Dedham, MA) after formic acid pre-treatment
for 30 min, and against p-tau (AT8 1:300, Innogenetics, Ghent,
Belgium). The immunoreaction was visualized using the EnVision
Plus/Horseradish Peroxidase system (DakoCytomation) and 3-3’-
diaminobenzidine as chromogen.
2.2. Oxysterol quantiﬁcation
Brain tissues were washed with phosphate-buffered saline
(PBS) to remove contaminating blood and stored at 80 °C before
being analyzed separately. Oxysterols were measured by isotope
dilution mass spectrometry, essentially as described elsewhere
[31] with the exception of the solid phase extraction (SPE) step,
which was repeated twice to eliminate cholesterol. Analyses were
run on an Agilent 6890N gas chromatograph equipped with a 7683
series automatic liquid sampler, and interfaced with an Agilent
5973 mass spectrometer (Agilent Technologies; Palo Alto, CA).
Separation was achieved on a 30 m capillary column (HP-5MS
300.25 mm ID, 0.25 mm thickness). The mass spectrometer was
set to the selected ion monitoring mode; the molecules were
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27-hydroxycholesterol, [2H7]-24-hydroxycholesterol, [2H7]-7α-hy-
droxycholesterol, [2H7]-7β-hydroxycholesterol, [2H7]-4α-hydro-
xycholesterol, and [2H7]-4β-hydroxycholesterol; 456 m/z for
[2H0]-27-hydroxycholesterol, [2H0]-24-hydroxycholesterol, [2H0]-
7α-hydroxycholesterol, [2H0]-7β-hydroxycholesterol, [2H0]-4α-
hydroxycholesterol, and [2H0]-4β-hydroxycholesterol; 481 m/z for
[2H7]-5α,6α-epoxycholesterol, and [2H7]-5β,6β-epoxycholesterol;
474 m/z for [2H0]-5α,6α-epoxycholesterol, and [2H0]-5β,6β-epox-
ycholesterol; 137 m/z for [2H6]-25-hydroxycholesterol, and 131 m/
z for [2H0]-25-hydroxycholesterol; 479 m/z for [2H7]-7-ketocho-
lesterol, and [2H0]-7-ketocholesterol (Avanti Polar Lipids). Quan-
tiﬁcation of oxysterols was by the internal standard ratio method.2.3. RNA extraction and cDNA synthesis
Total RNA was extracted using TRIzol Reagent (Applied Bio-
systems, Monza, Italy) following the manufacturer's instructions.
RNA was dissolved in RNase-free water fortiﬁed with RNase in-
hibitors (RNase SUPERase-In; Ambion, Austin, TX, USA). The
amount and purity (A260/A280 ratio) of the extracted RNA were
assessed spectrophotometrically. cDNAwas synthesized by reverse
transcription from 2 μg RNA with a commercial kit and random
primers (High-Capacity cDNA Reverse Transcription Kit; Applied
Biosystems) following the manufacturer's instructions.2.4. Real time RT-PCR
Singleplex real-time RT-PCR was performed on 30 ng of cDNA
using TaqMan Gene Expression Assay kits prepared for human
SIRT-1, COX-2, interleukin-1α (IL-1α), IL-6, IL-8, monocyte che-
motactic protein 1 (MCP-1), MMP-9, and β2-microglobulin, Taq-
Man Fast Universal PCR Master Mix, and 7500 Fast Real-Time PCR
System (Applied Biosystems). Negative controls did not include
cDNA. The oligonucleotide sequences are not revealed by the
manufacturer because of proprietary interests. The cycling para-
meters were as follows: 20 s at 95 °C for AmpErase UNG activation,
3 s at 95 °C for AmpliTaq Gold DNA polymerase activation, 40 cy-
cles of 3 s at 95 °C (melting), and 30 s at 60 °C (annealing⁄exten-
sion). The fractional cycle number (Ct) at which ﬂuorescence
passes the threshold in the ampliﬁcation plot of ﬂuorescence sig-
nal versus cycle number was determined for each gene considered.
The results were then normalized to the expression of β2-micro-
globulin, as housekeeping gene. Relative quantiﬁcation of target
gene expression was achieved with a mathematical method [32].Fig. 1. Distribution of neuroﬁbrillary changes in AD brain specimens. Immunohistoche
brown reaction product) revealed severe involvement of all regions of the cerebral cortex
sensory areas (B, Braak stage IV) or involve selectively the mesial temporal areas (A, Br3. Results
3.1. Neuropathological characterization of AD and control brains by
immunohistochemistry
In the four control brains (age at death: 60–71 years) there was
no evidence of Aβ or tau pathology. Signiﬁcant AD pathology (Aβ
deposits and neuroﬁbrillary changes) has been observed in the
other brains, which were classiﬁed based on the Braak staging
system of neuroﬁbrillary pathology [33]. Five brains were at stages
I or II (age at death: 72–86 years), and eight were at stages IV to VI
(age at death: 68–82 years) (Fig. 1).
In the brains at Braak stages I–II of neuroﬁbrillary changes, Aβ
deposits were moderate to numerous, with a clear preponderance
of preamyloid deposits (i.e. immunoreactive for Aβ but lacking the
tinctorial properties of amyloid as yellow ﬂuorescence after thio-
ﬂavine S staining). In the brains at Braak stages IV to VI of neu-
roﬁbrillary changes, the large majority of Aβ deposits were under
the form of senile plaques (ﬂuorescent after thioﬂavine S staining).
3.2. Oxysterol levels in the frontal and occipital cortex of AD brains
during AD progression
The study comprised autopsy specimens from the frontal and
occipital cortex of AD brains, classiﬁed as early or late AD based on
the Braak staging system of neuroﬁbrillary pathology (early AD:
stages I and II; late AD: stages IV–VI). In the control brains, the
presence of senile plaques and tau pathology was excluded. Oxy-
sterols were identiﬁed and quantiﬁed in brain samples by isotope
dilution gas chromatography/mass spectrometry, to determine
their levels in normal and AD brains. In particular, levels of oxy-
sterols in early and late AD brains were determined, to highlight
any changes in those levels during disease progression.
Of interest were data concerning the levels of ten oxysterols
recovered from the cerebral frontal and occipital cortex, two of
enzymatic origin (24-OH and 27-OH) (Fig. 2A), six of non-enzy-
matic origin (7-K, 4α-OH, 4β-OH, 7β-OH, α-epoxy and β-epoxy)
(Fig. 2C), and two of both enzymatic and non-enzymatic origin
(25-OH and 7α-OH) (Fig. 2B). Interestingly, it emerged that levels
of all oxysterols except 24-OH increased during disease progres-
sion, this increment becoming markedly signiﬁcant in late AD,
compared to control brains and even, in some cases, compared to
early AD brains. Levels of 7α-OH and 7β-OH were already elevated
in the early stages of AD (Fig. 2). Concerning 24-OH, in early AD its
level was similar to control brains, whereas it was signiﬁcantly
decreased at advanced disease stages (late AD), compared to
controls and early AD brains (Fig. 2A).
Of note, as Fig. 2 shows, an examination of oxysterol levels in
early and late AD brains clearly shows that they changemistry with monoclonal antibody AT8 to p-tau (immunoreactivity corresponds to
by neuroﬁbrillary changes (C, Braak stage VI), that can spare the primary motor and
aak stage II).
Fig. 2. Quantiﬁcation of oxysterols present in autopsy samples of frontal and occipital cortex from AD brains. Oxysterol levels were quantiﬁed by isotope dilution mass
spectrometry in ex vivo samples of AD brains classiﬁed by the Braak staging system. The ﬁgure gives the levels of: (A) two oxysterols of enzymatic origin, 24-hydro-
xycholesterol (24-OH) and 27-hydroxycholesterol (27-OH); (B) the oxysterols produced both enzymatically and non-enzymatically, 25-hydroxycholesterol (25-OH) and 7α-
hydroxycholesterol (7α-OH); (C) the oxysterols of non-enzymatic origin, 7-ketocholesterol (7-K), 7β-hydroxycholesterol (7β-OH), 5α,6α-epoxycholesterol (α-epoxy) and
5β,6β-epoxycholesterol (β-epoxy), 4α-hydroxycholesterol (4α-OH) and 4β-hydroxycholesterol (4β-OH). Early AD (Braak stages I, II); late AD (Braak stages IV–VI). Control brain
specimens: n¼4; early AD specimens: n¼5; late AD specimens: n¼8. Brain tissues from the frontal and occipital cortex were analyzed separately. *Po0.05,**Po0.01, and
***Po0.001 vs controls; #Po0.05 and ##Po0.01 vs early AD.
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versely, when all data regarding AD brains were grouped together
(total AD) without considering the disease stage of the donor, the
increase in levels of certain oxysterols (e.g. 25-OH, 27-OH, 4β-OH,
α-epoxy, and β-epoxy) was no longer signiﬁcant compared to
control brains (Table 1). The reduction of 24-OH level was lesssigniﬁcant, but still considerable.
These results suggest that subdivision of specimens by disease
stage may be of fundamental importance to clarify which events
or molecules might contribute to neurodegeneration. Considering
the brains of AD patients regardless of disease stage could ﬂatten
the results, and fail to reveal some important details, which only
Table 1
Identiﬁcation and quantiﬁcation of oxysterols in the frontal and occipital cortex of
AD brains (Total AD) by isotope dilution gas chromatography/mass spectrometry.
Control (ng/
mg tissue)
Total AD (ng/
mg tissue)
Enzymatic
oxysterols
24-hydroxycholesterol 20.1373.15 14.8674.41*
27-hydroxycholesterol 1.0170.59 1.6470.91
Both enzymatic
and non enzy-
matic oxysterols
25-hydroxycholesterol 0.1870.06 0.2570.10
7α-hydroxycholesterol 0.4470.23 1.7970.66***
Non enzymatic
oxysterols
7-ketocholesterol 1.4670.06 4.1071.90**
7β-hydroxycholesterol 2.2771.14 7.8673.70***
α-epoxycholesterol 0.9470.36 1.3970.73
β-epoxycholesterol 2.5071.14 4.3672.18
4α-hydroxycholesterol 0.2270.03 0.3070.18*
4β-hydroxycholesterol 0.3070.09 0.5270.36
AD, Alzheimer’s disease. Control brain specimens: n¼4; Total AD (Braak stages I to
VI) specimens: n¼13.
* Po0.05; ** Po0.01; *** Po0.001 vs controls.
Fig. 3. Measurement of the expression levels of CYP46A1 and CYP27A1 in AD brain
specimens. Gene expression was quantiﬁed by real-time RT-PCR in specimens at
different stages of AD. Brain specimens of healthy subjects were taken as controls.
Data, normalized to β2-microglobulin, are expressed as mean values7SD. Early AD
(Braak stages I, II); late AD (Braak stages IV to VI). Control brain specimens: n¼4;
early AD specimens: n¼5; late AD specimens: n¼8. Brain tissues from the frontal
and occipital cortex were analyzed separately. ***Po0.001vs controls; #Po0.05
and ###Po0.001 vs early AD.
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3.3. CYP46A1 and CYP27A1 expression levels in AD brain samples
Expression of the enzymes responsible for converting choles-
terol into the most widely studied oxysterols in the brain, 24-OH
and 27-OH, i.e. CYP46A1 and CYP27A1 respectively, was quantiﬁed
in the frontal and occipital cortex of ex vivo samples from normal
and AD brains. The AD brain specimens were subdivided by dis-
ease stage into early and late AD.
As shown in Fig. 3, CYP46A1 mRNA levels, measured by real
time RT-PCR, were signiﬁcantly decreased, in both early-stage AD
(about 40% vs control) and, more markedly, in late-stage AD
(about 80% vs control). Conversely, CYP27A1 mRNA levels were
increased in both early-stage (about 2.5-fold) and late-stage (about
4.5-fold) AD brains, compared to controls, but this increase was
only statistically signiﬁcant in late-stage AD. The results concern-
ing CYP46A1 and CYP27A1 expression levels (Fig. 3) respectively
reﬂect those for 24-OH and for 27-OH levels in AD brains (Fig. 2A):
the loss of 24-hydroxylase leads to the reduction of 24-OH levels,
and the increase of 27-hydroxylase leads to the accumulation of
27-OH.
3.4. Expression of some mediators involved in AD
neuroinﬂammation
To investigate a correlation between oxysterol content and in-
ﬂammatory response in AD brains, the expression of some pro-
inﬂammatory molecules in the cerebral frontal and occipital cortex
of AD patients was measured. Again brain specimens were divided
into two groups (early and late AD) by disease severity.
As Fig. 4 shows, mRNA levels of IL-1β, IL-6, and IL-8, and of
MMP-9, were markedly increased (about 5-fold vs controls) in late
AD brains, while MCP-1 expression was less up-regulated, but still
signiﬁcant in late AD samples. Concerning the enzyme COX-2,
which is involved in the inﬂammatory response, its overexpression
in AD brains clearly emerged, with a signiﬁcant increment already
in early AD (about 1.7-fold induction vs controls) (Fig. 5A).
Since SIRT-1 is involved in many inﬂammatory disorders, to
conﬁrm its role during AD progression, SIRT-1 mRNA levels were also
evaluated in the same autopsy samples of AD brains. Real-time RT-
PCR revealed a statistically-signiﬁcant decrease in SIRT-1 expression
in both early (about 50%) and late (about 60%) AD compared to
controls (Fig. 5B). These results suggest that the reduction of SIRT-1
levels during the progression of AD favors and ampliﬁesneuroinﬂammation and, consequently, neurodegeneration.
Of note, because of the consistent association between changes
in oxysterol levels (Fig. 2) and increased expression levels of in-
ﬂammatory molecules (Figs. 4 and 5A) in the AD brain, oxysterols
might be considered as new markers of both AD progression and
AD neuroinﬂammation.4. Discussion
The histopathological hallmarks of AD are senile plaques made
up of Aβ peptide, and NFT consisting of hyperphosphorylated tau
protein [1]. Aβ and p-tau have long been considered as the pri-
mary cause of AD, but alternative proposals have recently been
made, suggesting that oxidative stress, inﬂammation, and dysre-
gulated lipid homeostasis within the diseased brain may be the
key points leading to Aβ and p-tau formation and accumulation
[14,34]. However, the sequence of events occurring during AD
progression is not yet understood in detail, and the molecular
mechanisms remain to be fully elucidated. Therapeutic strategies
to counteract AD are thus still unsatisfactory.
The lack of speciﬁc markers for early diagnosis has stimulated
researchers to look for new molecules whose levels change in the
course of the disease. In this connection, oxysterols, cholesterol
oxidation products, might be new targets for monitoring AD pro-
gression: signiﬁcant changes in the concentrations of several
oxysterols have been observed in post-mortem AD brains com-
pared to healthy subjects. These changes in the brain might reﬂect
changes in oxysterol levels in the cerebrospinal ﬂuid (CSF) and
Fig. 4. Measurement of the expression levels of some inﬂammatory molecules in AD brain specimens. Gene expression of IL-1β, IL-6, IL-8, MCP-1 and MMP-9 was quantiﬁed
by real-time RT-PCR in specimens at different stages of AD. Brain specimens of healthy subjects were taken as controls. Data, normalized to β2-microglobulin, are expressed
as mean values7SD. Early AD (Braak stages I, II); late AD (Braak stages IV to VI). Control brain specimens: n¼4; early AD specimens: n¼5; late AD specimens: n¼8. Brain
tissues from the frontal and occipital cortex were analyzed separately. *Po0.05 and **Po0.01 vs controls; #Po0.05 and ##Po0.01 vs early AD.
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Increased oxysterol concentrations in the brain may promote
cellular damage, causing neuron dysfunction and degeneration,
and could contribute to neuroinﬂammation and amyloidogenesis
[14]. These compounds can also contribute to excitotoxic brain
injury [35]. In 2009, Hascalovici and collaborators identiﬁed 7α-
OH, 4β-OH, α- and β-epoxy, and 7-K in post-mortem human AD
brains, and their levels were higher at the mild cognitive impair-
ment (MCI) disease stage [17]. Recently, Ahonen and collaborators
reported that the two main oxysterols found in mouse AD brain
samples, in relatively high concentrations, were 24-OH (1.0–
1.6105 ng/g) and 27-OH (90–210 ng/g). Moreover, consistent le-
vels of 25-OH, 7α-OH, 7β-OH and 7-K were also detected [36].
Increased levels of 24-OH, 7-K, and β-epoxy have also been de-
tected in the areas of the rat hippocampus undergoing neuroin-
ﬂammation after kainite-induced excitotoxic injury [37,38].
To support the idea that changes in oxysterol content of the
brain might reﬂect changes in their levels in the peripheral cir-
culation, and in the light of the fact that oxysterols can cross the
BBB, the ﬂux of more than twenty cholesterol metabolites between
brain and circulation was recently analyzed in twenty AD patients.
Changes in concentrations, between jugular and forearm veins, of
eighteen oxysterols, ﬁve cholestenoic acids and three cholenoic
acids were measured. Among these cholesterol metabolites, 24-
OH, 7-OH-4-C, 7β-OH, 7-K and also 6-oxo-5α-hydroxycholesterol
were exported from the brain; of them, that exported in the lar-
gest quantities was 24-OH. Conversely, 27-OH was imported into
the brain [19]. Of note, 27-OH is one of the major oxysterols in the
blood circulation, and its high levels have been related to hy-
percholesterolemia and oxidative stress [39]. Two other choles-
terol metabolites, 7α,25-dihydroxycholest-4-en-3-one and 7α,
(25 R)26-hydroxycholest-4-en-3-one, are reported to be exportedfrom the brain [18]. Oxysterols and cholestenoic acids have also
been identiﬁed and quantiﬁed in mouse CSF, and the ﬁndings
compared with concentrations of the same metabolites found in
the plasma, in order to clarify cholesterol metabolism. Con-
centrations of oxysterols were lower in the CSF than in the plasma,
but 7α,24-dihydroxycholesterol and 7α,24-dihydroxycholest-4-
en-3-one, both of enzymatic origin, were only identiﬁed in the CSF
[40].
This paper presents, for the ﬁrst time, a systematic analysis of
oxysterols in the brains of patients with different stages of AD
development. Brain samples obtained at autopsy from individuals
affected by AD were examined by immunohistochemistry for the
two pathological hallmarks of this disease, extracellular amyloid
deposits and intraneuronal NFT. It was observed that the trends in
levels of 24-OH and 27-OH, the two oxysterols of enzymatic origin,
were opposed during the course of the disease: in the early stages
of AD, levels of 24-OH and 27-OH were, respectively, slightly be-
low and slightly above those of controls. Of note, at the later stages
of AD, 24-OH levels were markedly decreased (about 40%)
compared to control brains, while 27-OH levels were approxi-
mately double those of controls (Fig. 2A); both these changes were
statistically signiﬁcant compared to levels of the two oxysterols in
early stages, stressing that changes in their concentrations play an
important role in the end-phase of the disease. The same trend as
27-OH was observed for 25-OH, β-epoxy, 4α-OH, and 4β-OH,
oxysterols mainly deriving from cholesterol autoxidation by ROS
during oxidative stress (Fig. 2B and 2C). Concerning the other
oxysterols, 7α-OH, 7β-OH, 7-K and α-epoxy, the levels increased
progressively from the earliest stages of the disease, peaking in the
late stages, in most cases the difference being signiﬁcant com-
pared to controls (Fig. 2B and 2C).
If the levels of the various oxysterols at early and at late AD
Fig. 5. Measurement of the expression levels of COX-2 and SIRT-1 in AD brain
specimens. Gene expression of COX-2 and SIRT-1 was quantiﬁed by real-time RT-
PCR in specimens at different stages of AD. Brain specimens of healthy subjects
were taken as controls. Data, normalized to β2-microglobulin, are expressed as
mean values7SD. Early AD (Braak stages I, II); late AD (Braak stages IV–VI). Control
brain specimens: n¼4; early AD specimens: n¼5; late AD specimens: n¼8. Brain
tissues from the frontal and occipital cortex were analyzed separately. *Po0.05 and
***Po0.001 vs controls.
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centrations are evident and statistically signiﬁcant; this is parti-
cular so at the later disease stages. In contrast, analyzing all AD
brain specimens together, some differences in oxysterol levels are
no longer signiﬁcant versus controls (Table 1). In particular, con-
cerning the oxysterols generally considered to be potentially in-
volved in AD, 24-OH and 27-OH, it was observed that the reduc-
tion in the former was much less signiﬁcant versus controls, while
the increase in the latter was no more signiﬁcant versus controls
(Table 1).
These results highlight the importance of discriminating
among the different stages of progression of the disease when
performing any analysis, in order to clarify at what stage bio-
chemical or molecular changes occur; this is necessary in order to
develop targeted therapeutic strategies for use at the appropriate
time, so as to prevent or reduce neuronal damage.
The same analytical approach was applied to measuring ex-
pression levels of the cholesterol hydroxylases CYP46A1 and
CYP27A1, respectively responsible for the formation of 24-OH and
of 27-OH. It was found that CYP46A1 expression dramatically
decreased during AD progression. In early AD brains it was already
signiﬁcantly reduced, by about 40%, but in late AD brains it was
reduced by as much as 80% (Fig. 3A). Conversely, CYP27A1expression was markedly increased, in particular in the later
phases of AD (Fig. 3B). These results are in agreement with the
trend in 24-OH and 27-OH levels, quantiﬁed at early and late
stages in AD brains. The signiﬁcant decrement of both CYP46A1
and 24-OH in the late stages of AD reﬂects a selective loss of
neuronal cells expressing the 24-hydroxylase. As demonstrated by
Brown 3rd and collaborators, CYP46A1 is expressed in neurons
and astrocytes in the normal brain, but during AD progression the
levels of 24-OH decrease markedly because of the neuronal da-
mage [41]. However, it has been observed that, in the damaged
area, and especially around senile plaques, there is an ectopic in-
duction of CYP46A1 in the astrocytes, leading to some 24-OH
production, but without compensating for the decrease of that
oxysterol [41,42]. Conversely, various reasons might explain the
marked increment of CYP27A1 and 27-OH in the end-phases of
AD. Immunocytochemical studies have shown that, in the normal
brain, CYP27A1 is expressed in the neurons, astrocytes and oli-
godendrocytes. In AD brains, the number of neurons expressing
27-hydroxylases decreases and, as a consequence of neuron loss,
expression of CYP27A1 may also be reduced; however, 27-OH le-
vels remain elevated because CYP27A1 is expressed in astrocytes
and oligodendrocytes, leading to in situ generation of 27-OH [41].
Accumulation of 27-OH in the brain is also due to the increased
ﬂux of this oxysterol across the BBB, either because of hypercho-
lesterolemia associated to oxidative stress [21], or of damaged BBB
integrity [20]. An alternative explanation for the accumulation of
27-OH is the reduced activity of CYP7B, the neuronal enzyme re-
sponsible for 27-OH metabolism; this reduction arises from the
reduced CYP7B expression in the brain of AD patients, because of
neuron loss [43].
From these considerations, it is clear that the balance between
24-OH and 27-OH levels is important, and that an increased ratio
of 27-OH to 24-OH in AD brains is consistent with AD pathogen-
esis. Thus it is likely that reduced levels of 24-OH may accelerate
disease progression, and that the increased levels of 27-OH may be
insufﬁcient to compensate for this: the shift in balance between
the two oxysterols might lead to increased generation and accu-
mulation of Aβ and NFT with consequent neurodegeneration
[16,21,44].
Besides changes in oxysterol levels, it has also become evident
that inﬂammation and oxidative stress are self-reinforcing during
AD progression: inﬂammation can be triggered or enhanced by
oxidative stress, through activation of the redox sensitive tran-
scription factor NF-κB, and vice versa [14,23].
The brain regions that are vulnerable to neurodegeneration, as
in the case of AD, exhibit increased oxidative damage, in terms of
DNA oxidation, protein oxidation, and lipid peroxidation, together
with depletion of antioxidant enzymes; these occur before the
appearance of senile plaques and NFT [45–47].
Elevated inﬂammatory response, characterized by the release
of cytokines, adhesion molecules, proteolytic enzymes and other
inﬂammatory mediators, has been detected in regions of the brain
of AD patients, both post-mortem and in vivo, and in animal models
of AD [26,48–50]. Interestingly, in recent years genetic variations
in inﬂammation related genes have been investigated in AD.
Several genetic studies have reported signiﬁcant associations be-
tween different polymorphisms of genes encoding for pro- and
anti-inﬂammatory molecules and AD [51,52]. It has also been
observed that inﬂammatory changes are a relatively early patho-
genic events in AD pathology, and that they precede the late
stages, characterized by tau-related pathology [53]. However, the
precise role played by pro-inﬂammatory molecules in AD remains
controversial. In the early stages of AD, neuroinﬂammation ap-
pears to be beneﬁcial in slowing AD progression, whereas in the
later stages, chronic inﬂammation is detrimental to neurons [54].
This study provides evidence that the expression levels of
Fig. 6. A hypothetical scheme for the involvement of oxysterols in the different stages of AD progression.
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brain samples. In particular, IL-1β, IL-6, and IL-8, MCP-1 and MMP-
9 mRNA levels were all signiﬁcantly up-regulated in brain speci-
mens from the frontal and occipital cortex of late-stage AD (Fig. 4).
These inﬂammatory molecules are produced by glia cells and
neurons. Interleukins are important mediators for glia cell re-
cruitment and activation, as is leukocyte inﬁltration around the
areas of neuroinﬂammation; interleukins can also initiate the
further production of signaling molecules and stimulate produc-
tion of other inﬂammatory mediators [25,26]. Expression of MMP-
9, a major MMP that has been identiﬁed in neuroinﬂammation, is
regulated, among others factors, by cytokines [55].
Furthermore, it is increasingly apparent that the COX-2-de-
pendent pathway is associated with neuroinﬂammation and
neurodegeneration. Indeed, COX-2 expression and activity is up-
regulated during neuroinﬂammation, with subsequent production
of prostaglandins, and its overexpression is mainly observed in
damaged neurons, which can be promoted by cytokine release
[28,56–58]. Further, leukocyte migration across a damaged BBB is
also inﬂuenced by COX-2 production, supporting the idea that
increased peripheral inﬂammation is capable of propagating sus-
tained and damaging neuroinﬂammation [59]. In this connection,
among the lipid mediators produced by COX-2, prostaglandin E2
activates NF-κB, which, in turn, may stimulate leukocyte recruit-
ment into the inﬂamed brain by inducing MCP-1 transcription
[60,61]. The present study investigated the implication of COX-2,
the key player in the neuroinﬂammatory response. A statistically
signiﬁcant increase (about 1.5-fold vs controls) of COX-2 expres-
sion levels was observed in the early stage of the disease (Fig. 5A).
The data are in agreement with other studies on patients at dif-
ferent stages of AD pathology, which show increased neuronal
expression of COX-2 in the neocortex of patients with early Braak
stage AD [62]. Moreover, as previously demonstrated in vitro inhuman neuroblastoma SH-SY5Y cells, the oxysterols mainly in-
volved in AD are capable of synthesizing COX-2 in response to
inﬂammatory mediator release [63]. The results reported here
thus conﬁrm the involvement of oxysterols in neuroinﬂammation.
Another molecule involved in the pathology of AD is SIRT-1, a
deacetylase predominantly localized in nuclei, which takes part in
several crucial neuroprotective pathways [64]. It has been de-
monstrated to regulate the anti-inﬂammatory response by acti-
vating the nuclear receptor liver X receptor (LXR) via deacetylation
of Lys432 [65], or by inhibiting NF-κB through deacetylation of the
Lys310 residue of RelA/p65 [66]. Overexpression of SIRT-1 or its
activation by resveratrol have also been shown to be neuropro-
tective by markedly reducing NF-κB signaling stimulated by Aβ, in
microglial cells [67]. Another mechanism by which SIRT-1 exerts
its neuroprotective effect concerns its ability to reduce the pa-
thological accumulation of Aβ both in vitro and in vivo. In parti-
cular, SIRT-1 increases α-secretase production and activity in
mouse primary neurons [68]. Moreover, SIRT-1 overexpression,
mediated by its agonist resveratrol, leads to the reduction of oli-
gomerized Aβ peptides and of oxidative stress [69]. SIRT-1 also
inhibits the tau-related AD phenotype: it directly deacetylates tau
protein at multiple residues, making the protein more susceptible
to proteasomal degradation. SIRT-1 deﬁciency leads to hyper-
acetylation of tau, with the consequent accumulation of p-tau [70].
Taking into account these ﬁndings, it may be assumed that the
decreased levels of SIRT-1 during AD progression could accelerate
neurodegeneration by: i) activating NF-κB in microglia, thus pro-
moting neuroinﬂammation; ii) inhibiting the expression of α-se-
cretase, leading to Aβ production; iii) favoring tau accumulation by
inhibiting its clearance. Therefore, therapeutic up-regulation of
SIRT-1 may provide opportunities for the amelioration of AD
neuropathology and related conditions by protecting against
neuronal loss.
G. Testa et al. / Redox Biology 10 (2016) 24–3332The signiﬁcant decrease in SIRT-1 levels in autopsy samples
from AD patients has already been reported, but its crucial role
during the different phases of AD progression has not been elu-
cidated. Julien and collaborators, after having analyzed various
cerebral regions in autopsy specimens, provided the ﬁrst evidence
of a down-regulation of SIRT-1 in the cerebral cortex of patients
with MCI or AD. They reported that SIRT-1 decreases in parallel
with the accumulation of tau protein, and that the greater loss of
SIRT-1 protein and mRNA levels is probably a relatively late event
[29].
In contrast, the present study found a highly signiﬁcant SIRT-1
decrease already in early AD specimens, becoming even greater in
late AD (Fig. 5B). These data are in agreement with a study by Lutz
and collaborators, which found a loss of SIRT-1 during AD pro-
gression by the Braak staging system of neuroﬁbrillary degenera-
tion. Alongside the decrease in SIRT-1 expression, which is in-
versely correlated with tau and amyloid protein accumulation,
they also observed that the loss of SIRT-1 is dependent on the
neuronal population, after analyzing different brain subregions
[71].
Concerning the involvement of COX-2 and SIRT-1 in neuroin-
ﬂammation, it is clear from the present data that SIRT-1 expression
is inversely proportional to the expression of COX-2 (Fig. 5). It may
thus be suggested that the loss of SIRT-1 during AD progression
sustains neuroinﬂammation and neuronal damage. In support of
this hypothesis, it has been demonstrated that docosahexaenoic
acid, a representative omega-3 polyunsaturated fatty acid, protects
against obesity-associated inﬂammation by suppressing insulin-
induced expression of COX-2, through up-regulation of SIRT-1, in
human colon epithelial cells [72].
In summary, this study provides important insights into the
contribution of oxysterols, as well as that of SIRT-1 and other in-
ﬂammatory mediators, to the occurrence and development of
neurodegenerative changes in AD (Fig. 6). Further, because the
concentration of certain oxysterols in CSF and the peripheral cir-
culation reﬂects the number of metabolically-active neurons in the
brain [14] and, thus, the progression of AD, their levels in these
biological ﬂuids might be associated to the degree of neuronal
damage; this might provide a means of identifying early or late
phases of the disease. Another promising serum protein marker
for early AD could be SIRT-1 [73]. For this reason, oxysterols and
SIRT-1 might represent novel predictive biomarkers for the early
diagnosis of AD.5. Conclusions
Further studies will be needed to identify all the molecular
pathways that are modulated or altered by oxysterols at different
stages of AD, in order to ﬁnd targeted therapeutic strategies that
may have different effects on distinct vulnerable brain areas, to
prevent or to treat this disabling disease.Acknowledgments
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